Price Chart

Executive Summary

Incyte announced a definitive agreement to acquire Vega Therapeutics (a Star Therapeutics subsidiary) for $1.25 billion upfront, plus up to $750 million in sales milestones, totaling up to $2.0 billion. The deal adds VGA039, a Phase 3 monoclonal antibody for von Willebrand disease, to Incyte's hematology portfolio. The transaction is expected to close in Q3 2026, subject to HSR review, and will result in an ~$1.25 billion R&D charge.

Key Facts

• Incyte to acquire Vega Therapeutics for $1.25 billion upfront, with up to $750 million in sales milestone payments (total potential consideration up to $2.0 billion).
• VGA039 is a first-in-class, Phase 3 monoclonal antibody targeting Protein S for von Willebrand disease (VWD), with FDA Breakthrough Therapy, Fast Track, orphan drug, and rare pediatric disease designations.
• VGA039 is already in the Phase 3 VIVID-6 study (NCT07115004), a global single-arm crossover study for all VWD types.
• Transaction expected to close in Q3 2026, pending Hart-Scott-Rodino antitrust review.
• Incyte expects an R&D charge of approximately $1.25 billion in Q3 and full-year 2026 GAAP and non-GAAP results.
• Approximately 135,000 people in the US have been diagnosed with VWD; current prophylactic options require 2-3 IV infusions per week, while VGA039 is a subcutaneous once-monthly therapy.

Financial Impact

$1.25 billion upfront cash consideration plus up to $750 million in sales milestones; expected ~$1.25 billion R&D charge in Q3 2026.

Risk Factors

• HSR review could delay or block the transaction.
• VGA039 is still in Phase 3; pivotal data readout and regulatory approval are not guaranteed.
• The $1.25 billion upfront cost will pressure near-term cash and GAAP earnings.
• Integration risk and potential for lower-than-expected commercial uptake in the VWD market.

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

US Market Status